Ashley Tolbert, MD
Interventional Pain Medicine · Indianapolis, INNPI 1366821449
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,419 of the $15,245 with a category attached, or 61.8%. 50 manufacturers reported payments, led by Medtronic at 26.3% of the total. Reporting peaked in 2019 at $6,096 and has fallen 67.2% since, to $1,999 in 2025.
Across 407 payments — averaging $37.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$3K
- Abbott$2K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$638
- ANI Pharmaceuticals, Inc.$547
- plus $4K from 44 others
What the payments were for
- Grants$3,75025%
- Travel & lodging$1,92313%
- Food & beverage$9,41962%
- Education$1531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMED$3,750
- Proclaim Family of SCS IPGs$1,854
- Superion Indirect Decompression System$862
- SPECTRA WAVEWRITER$462
- WaveWriter Alpha Prime 16$421
- mild Device Kit$243
- CFNS StimQ Peripheral Nerve StimulatorSystem$189
- SCS FreedonSpinal Cord Stimulator$189
- GENERAL PAIN MANAGEMENT$148
- UBRELVY$120
- StimQ Peripheral Nerve StimulatorSystem$120
- WAVEWRITER ALPHA$120
- Superion ISS$112
How this compares
$15,245 in reported general payments places this provider in the 85th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 45 | $32,459 |
| Buprenorphine | 60 | $20,188 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 77 | $16,623 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 691 | $16,219 |
| UbrelvyUbrogepant | 11 | $13,374 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 424 | $13,151 |
| OxycontinOxycodone Hcl | 29 | $11,067 |
| Lidocaine | 53 | $7,188 |
| Xtampza ErOxycodone Myristate | 23 | $7,110 |
| Pregabalin | 232 | $6,886 |
| Fentanyl | 73 | $5,672 |
| Gabapentin | 207 | $2,448 |
| Morphine Sulfate ErMorphine Sulfate | 71 | $2,100 |
| Oxycodone Hcl | 104 | $1,899 |
| Naloxone Hcl | 22 | $1,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $79 | $39,57068 claims |
| AbbVieUbrelvy | $1,753 | $13,37411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 interventional pain medicine providers in Indiana.
Other interventional pain medicine in Indianapolis
- David GordonIndianapolis$28K
- Vinayak BelamkarIndianapolis$28K
- Jocelyn BushIndianapolis$20K
- Edward KowlowitzIndianapolis$15K
- Kristin GossIndianapolis$7K
- Caroline AsavaIndianapolis$3K
- Keiona WallerIndianapolis$3K
- Michael DorwartIndianapolis$3K
- Dena SeifertIndianapolis$2K
- David RatzmanIndianapolis$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.